pharma tariffs on global drug supply chains, manufacturing onshoring investments, and digital IT strategy for compliance.
In the present post hoc analysis published in Diabetes Care , Klein and colleagues examined data on the 16 996 adults participating in four large randomised, double-blind, placebo-controlled clinical trials assessing the safety and efficacy of GLP-1 RAs: the LEADER trial of liraglutide, the STEP 2 and SUSTAIN 6 trials of subcutaneous semaglutide, and the PIONEER 6 trial of oral semaglutide
Rotem Ben-Shachar was first author
They support brain repair, neuroplasticity, and overall cognitive function, which can lead to long-term improvements
Encore: behavioural animal models of stress, depression and mood disorders